← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #878 OF 1,000 MOST-CITED

Complaints reviewed by Quality Control Unit

FDA cited this observation 16 times across 16 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs16
BY FISCAL YEAR
FY20251
FY20243
FY20231
FY20222
FY20211
FY20191
FY20184
FY20173

How FDA worded it — real examples

Written procedures describing the handling of complaints do not include provisions for a determination as to the need for an investigation of any unexplained discrepancy.

Perfomics Analytical Labs LLP · Hyderabad · Drugs · 2025-06-04

Written procedures describing the handling of complaints do not include provisions for explaining the reasons for the failure of the batch or any of its components to meet specifications.

Ocean Healthcare Pvt Ltd · Chengalpattu District · Drugs · 2024-06-14

Written procedures describing the handling of complaints do not include provisions for review by the quality control unit of any complaint involving the possible failure of a drug product to meet any of its specifications.

The Gorilla Glue Company · Cincinnati, Ohio · Drugs · 2024-02-23

Written procedures describing the handling of complaints do not include provisions for a determination as to the need for an investigation of any unexplained discrepancy.

Alkermes Inc · Wilmington, Ohio · Drugs · 2023-10-19

Written procedures describing the handling of complaints do not include provisions for review by the quality control unit of any complaint involving the possible failure of a drug product to meet any of its specifications, a determination as to the need for an investigation of any unexplained discrepancy and explaining the reasons for the failure of the batch or any of its components to meet specifications.

Uniao Quimica Farmaceutica Nacional SA · Guarulhos · Drugs · 2023-08-09

Written procedures describing the handling of complaints do not include provisions for review by the quality control unit of any complaint involving the possible failure of a drug product to meet any of its specifications and a determination as to the need for an investigation of any unexplained discrepancy.

Advanced Cosmetic Research Laboratories, Inc. · Chatsworth, California · Drugs · 2022-04-27

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Quality risk managementPharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →